Home Biosimilar Antibodies Cytoskeletal Signaling Others Crizanlizumab (Anti-P-Selectin / CD62p)
For research use only. Not for use in humans.

Crizanlizumab (Anti-P-Selectin / CD62p)

Synonyms: null

Crizanlizumab (Anti-P-Selectin / CD62p) is a humanized monoclonal immunoglobulin G1 anti-P-selectin antibody with vaso-protective and anti-vaso-occlusive properties. MW: 144.24 kD.

Crizanlizumab (Anti-P-Selectin / CD62p)

1 Citation

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: A237401 Purity: 99% Protein concentration: 4.18mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Crizanlizumab (Anti-P-Selectin / CD62p) is a humanized monoclonal immunoglobulin G1 anti-P-selectin antibody with vaso-protective and anti-vaso-occlusive properties. MW: 144.24 kD.

Product Details

CAS No. 1690318-25-2
Molecular Weight 144.24 kDa
Isotype Human IgG2SA
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04657822 RECRUITING Drug: Crizanlizumab Sickle Cell Disease Novartis Pharmaceuticals 2021-06-10 PHASE4
NCT06439082 RECRUITING Drug: Placebo Sickle Cell Disease Novartis Pharmaceuticals 2024-10-24 PHASE3
NCT05909618 RECRUITING Drug: Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [AD Advanced Glioblastoma; Metastatic Melanoma in the Central Nervous System; MGMT-Unmethylated Glioblastoma Sheba Medical Center 2023-07-11 PHASE2
NCT05469828 NOT_YET_RECRUITING Drug: Crizanlizumab Sickle Cell Disease Children's Hospital Los Angeles 2024-07-01 PHASE1; PHASE2
NCT04611880 COMPLETED Drug: Crizanlizumab RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy Washington University School of Medicine 2021-01-25 PHASE2
NCT03474965 COMPLETED Drug: Crizanlizumab Sickle Cell Disease (SCD) Novartis Pharmaceuticals 2018-10-01 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-06-08)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.